{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T18:25:11Z","timestamp":1787250311050,"version":"build-2736575974"},"update-to":[{"DOI":"10.1371\/journal.pcbi.1014632","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000}}],"reference-count":58,"publisher":"Public Library of Science (PLoS)","issue":"8","license":[{"start":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["1745302"],"award-info":[{"award-number":["1745302"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["4R33AI161805-05"],"award-info":[{"award-number":["4R33AI161805-05"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012802","name":"Ragon Institute of MGH, MIT and Harvard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012802","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.ploscompbiol.org"],"crossmark-restriction":false},"short-container-title":["PLoS Comput Biol"],"abstract":"<jats:p>Despite decades of research, an effective HIV vaccine or cure has not yet been developed. An important reason is the virus\u2019s mutability, which allows it to rapidly evade human immune responses. Often, the virus also takes advantage of epistatic pathways to evolve escape mutations through compensatory effects that allow maintaining its fitness. We used a fitness landscape of HIV, which explicitly considers interactions between mutations, to design an immunogen that contains parts of the proteome that are \u201cmultidimensionally\u201d conserved. Based on inferred fitness landscapes, these regions are predicted to be under mutational constraints. Our immunogen also incorporates predicted immunogenic regions and offers broad coverage for the Caucasian population. We further investigate the relative contributions of various proteins in our design and compare properties with other immunogens. We hope that our proposed immunogen will serve as a candidate for experimental evaluation in pre-clinical studies in T cell-based vaccine or immunotherapy contexts.<\/jats:p>","DOI":"10.1371\/journal.pcbi.1014632","type":"journal-article","created":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:58:26Z","timestamp":1786730306000},"page":"e1014632","update-policy":"https:\/\/doi.org\/10.1371\/journal.pcbi.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design of an immunogen containing multidimensionally conserved and immunogenic parts of the HIV proteome"],"prefix":"10.1371","volume":"22","author":[{"given":"Eric","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1268-9602","authenticated-orcid":true,"given":"Arup K.","family":"Chakraborty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,8,14]]},"reference":[{"issue":"1","key":"pcbi.1014632.ref001","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/s41572-023-00452-3","article-title":"HIV infection","volume":"9","author":"L-G Bekker","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"pcbi.1014632.ref002","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1177\/003335491012500221","article-title":"Access to antiretroviral therapy for adults and children with HIV infection in developing countries: horizons studies, 2002\u20132008","volume":"125","author":"A Sarna","year":"2010","journal-title":"Public Health Rep"},{"issue":"5","key":"pcbi.1014632.ref003","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1093\/cid\/ciab541","article-title":"Time to viral rebound after interruption of modern antiretroviral therapies","volume":"74","author":"JZ Li","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"2","key":"pcbi.1014632.ref004","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","article-title":"A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population","volume":"7","author":"A Chawla","year":"2018","journal-title":"Infect Dis Ther"},{"key":"pcbi.1014632.ref005","doi-asserted-by":"crossref","first-page":"590780","DOI":"10.3389\/fimmu.2020.590780","article-title":"Major scientific hurdles in HIV vaccine development: historical perspective and future directions","volume":"11","author":"T Ng\u2019uni","year":"2020","journal-title":"Front Immunol"},{"key":"pcbi.1014632.ref006","article-title":"The determination of HIV-1 RT mutation rate, its possible allosteric effects, and its implications on drug resistance","author":"JY Yeo","year":"2020","journal-title":"Viruses"},{"issue":"9","key":"pcbi.1014632.ref007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1002251","article-title":"Extremely high mutation rate of HIV-1 in vivo","volume":"13","author":"JM Cuevas","year":"2015","journal-title":"PLoS Biol"},{"issue":"11","key":"pcbi.1014632.ref008","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/s41590-018-0235-7","article-title":"Recent progress in broadly neutralizing antibodies to HIV","volume":"19","author":"D Sok","year":"2018","journal-title":"Nat Immunol"},{"key":"pcbi.1014632.ref009","doi-asserted-by":"crossref","first-page":"7588","DOI":"10.1128\/JVI.00734-12","article-title":"The development of CD4 binding site antibodies during HIV-1 infection","volume":"86","author":"M Lynch","year":"2012","journal-title":"J Virol"},{"issue":"1","key":"pcbi.1014632.ref010","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1080\/22221751.2020.1713707","article-title":"Broadly neutralizing antibodies for HIV-1: efficacies, challenges and opportunities","volume":"9","author":"Y Liu","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"pcbi.1014632.ref011","doi-asserted-by":"crossref","first-page":"171","DOI":"10.3389\/fimmu.2014.00171","article-title":"T cell responses to viral infections - opportunities for Peptide vaccination","volume":"5","author":"S Rosendahl Huber","year":"2014","journal-title":"Front Immunol"},{"key":"pcbi.1014632.ref012","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coi.2015.05.001","article-title":"HIV therapeutic vaccines: moving towards a functional cure","volume":"35","author":"GH Mylvaganam","year":"2015","journal-title":"Curr Opin Immunol"},{"issue":"6353","key":"pcbi.1014632.ref013","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1038\/354453a0","article-title":"Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition","volume":"354","author":"RE Phillips","year":"1991","journal-title":"Nature"},{"issue":"4","key":"pcbi.1014632.ref014","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/mt.2016.3","article-title":"Novel conserved-region T-cell mosaic vaccine with high global HIV-1 coverage is recognized by protective responses in untreated infection","volume":"24","author":"B Ondondo","year":"2016","journal-title":"Mol Ther"},{"issue":"2","key":"pcbi.1014632.ref015","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/mt.2013.248","article-title":"Vaccine-elicited human T cells recognizing conserved protein regions inhibit HIV-1","volume":"22","author":"N Borthwick","year":"2014","journal-title":"Mol Ther"},{"issue":"10","key":"pcbi.1014632.ref016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0000984","article-title":"Design and pre-clinical evaluation of a universal HIV-1 vaccine","volume":"2","author":"S L\u00e9tourneau","year":"2007","journal-title":"PLoS One"},{"issue":"4","key":"pcbi.1014632.ref017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176418","article-title":"Novel, in-natural-infection subdominant HIV-1 CD8+ T-cell epitopes revealed in human recipients of conserved-region T-cell vaccines","volume":"12","author":"N Borthwick","year":"2017","journal-title":"PLoS One"},{"issue":"22","key":"pcbi.1014632.ref018","doi-asserted-by":"crossref","first-page":"12608","DOI":"10.1128\/JVI.01369-07","article-title":"Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A","volume":"81","author":"MA Brockman","year":"2007","journal-title":"J Virol"},{"key":"pcbi.1014632.ref019","doi-asserted-by":"crossref","first-page":"11660","DOI":"10.1038\/ncomms11660","article-title":"Relative rate and location of intra-host HIV evolution to evade cellular immunity are predictable","volume":"7","author":"JP Barton","year":"2016","journal-title":"Nat Commun"},{"issue":"2","key":"pcbi.1014632.ref020","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/vez029","article-title":"Modelling and in vitro testing of the HIV-1 Nef fitness landscape","volume":"5","author":"JP Barton","year":"2019","journal-title":"Virus Evol"},{"issue":"3","key":"pcbi.1014632.ref021","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.immuni.2012.11.022","article-title":"Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design","volume":"38","author":"AL Ferguson","year":"2013","journal-title":"Immunity"},{"issue":"4","key":"pcbi.1014632.ref022","article-title":"Fitness landscape of the human immunodeficiency virus envelope protein that is targeted by antibodies","volume":"115","author":"RHY Louie","year":"2018","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"pcbi.1014632.ref023","article-title":"The fitness landscape of HIV-1 gag: advanced modeling approaches and validation of model predictions by in vitro testing","volume":"10","author":"JK Mann","year":"2014","journal-title":"PLoS Comput Biol"},{"issue":"5","key":"pcbi.1014632.ref024","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2022496118","article-title":"Adenovirus-vectored vaccine containing multidimensionally conserved parts of the HIV proteome is immunogenic in rhesus macaques","volume":"118","author":"DK Murakowski","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"pcbi.1014632.ref025","doi-asserted-by":"crossref","first-page":"062705","DOI":"10.1103\/PhysRevE.88.062705","article-title":"Spin models inferred from patient-derived viral sequence data faithfully describe HIV fitness landscapes","volume":"88","author":"K Shekhar","year":"2013","journal-title":"Phys Rev E Stat Nonlin Soft Matter Phys"},{"key":"pcbi.1014632.ref026","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/srep00200","article-title":"Networks link antigenic and receptor-binding sites of influenza hemagglutinin: mechanistic insight into fitter strain propagation","volume":"1","author":"V Soundararajan","year":"2011","journal-title":"Sci Rep"},{"issue":"20","key":"pcbi.1014632.ref027","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1073\/pnas.0915087107","article-title":"Protein dynamics investigated by inherent structure analysis","volume":"107","author":"F Rao","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6439","key":"pcbi.1014632.ref028","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1126\/science.aav5095","article-title":"Structural topology defines protective CD8+ T cell epitopes in the HIV proteome","volume":"364","author":"GD Gaiha","year":"2019","journal-title":"Science"},{"issue":"28","key":"pcbi.1014632.ref029","doi-asserted-by":"crossref","first-page":"11530","DOI":"10.1073\/pnas.1105315108","article-title":"Coordinate linkage of HIV evolution reveals regions of immunological vulnerability","volume":"108","author":"V Dahirel","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"pcbi.1014632.ref030","doi-asserted-by":"crossref","first-page":"032601","DOI":"10.1088\/1361-6633\/aa574a","article-title":"Rational design of vaccine targets and strategies for HIV: a crossroad of statistical physics, biology, and medicine","volume":"80","author":"AK Chakraborty","year":"2017","journal-title":"Rep Prog Phys"},{"issue":"11","key":"pcbi.1014632.ref031","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1093\/infdis\/jiu809","article-title":"Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection","volume":"211","author":"TA Crowell","year":"2015","journal-title":"J Infect Dis"},{"issue":"1","key":"pcbi.1014632.ref032","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","article-title":"mRNA vaccines in disease prevention and treatment","volume":"8","author":"G Zhang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"pcbi.1014632.ref033","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"N Chaudhary","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"pcbi.1014632.ref034","doi-asserted-by":"crossref","first-page":"102311","DOI":"10.1016\/j.isci.2021.102311","article-title":"Learning from HIV-1 to predict the immunogenicity of T cell epitopes in SARS-CoV-2","volume":"24","author":"A Gao","year":"2021","journal-title":"iScience"},{"issue":"7681","key":"pcbi.1014632.ref035","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","volume":"551","author":"M \u0141uksza","year":"2017","journal-title":"Nature"},{"key":"pcbi.1014632.ref036","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.4049\/jimmunol.1700893","article-title":"NetMHCpan-4.0: improved peptide\u2013MHC class I interaction predictions integrating eluted ligand and peptide binding affinity data","volume":"199","author":"V Jurtz","year":"2017","journal-title":"J Immunol"},{"key":"pcbi.1014632.ref037","article-title":"The Immune Epitope Database (IEDB): 2024 update","volume":"53","author":"IEDB Curation Team Members","year":"2025","journal-title":"Nucleic Acids Res"},{"key":"pcbi.1014632.ref038","article-title":"Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools","volume":"48","author":"FF Gonzalez-Galarza","year":"2020","journal-title":"Nucleic Acids Res"},{"key":"pcbi.1014632.ref039","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1742-4690-10-7","article-title":"HIV-1 subtype distribution and its demographic determinants in newly diagnosed patients in Europe suggest highly compartmentalized epidemics","volume":"10","author":"AB Abecasis","year":"2013","journal-title":"Retrovirology"},{"issue":"6","key":"pcbi.1014632.ref040","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1007\/s13365-013-0206-6","article-title":"Effect of HIV clade differences on the onset and severity of HIV-associated neurocognitive disorders","volume":"19","author":"W Tyor","year":"2013","journal-title":"J Neurovirol"},{"key":"pcbi.1014632.ref041","article-title":"mRNA-based anti-TCR CDR3 tumour vaccine for T-cell lymphoma","author":"M Tusup","year":"2021","journal-title":"Pharmaceutics"},{"issue":"7662","key":"pcbi.1014632.ref042","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"U Sahin","year":"2017","journal-title":"Nature"},{"key":"pcbi.1014632.ref043","unstructured":"Best-defined CTL\/CD8 epitope summary. In: HIV molecular immunology database."},{"key":"pcbi.1014632.ref044","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1186\/1479-5876-9-208","article-title":"Definition of the viral targets of protective HIV-1-specific T cell responses","volume":"9","author":"B Mothe","year":"2011","journal-title":"J Transl Med"},{"issue":"15","key":"pcbi.1014632.ref045","doi-asserted-by":"crossref","first-page":"7641","DOI":"10.1128\/JVI.00182-09","article-title":"Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells","volume":"83","author":"H Streeck","year":"2009","journal-title":"J Virol"},{"issue":"9","key":"pcbi.1014632.ref046","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2018338118","article-title":"Design of immunogens to elicit broadly neutralizing antibodies against HIV targeting the CD4 binding site","volume":"118","author":"S Conti","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"pcbi.1014632.ref047","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003618","article-title":"A next-generation cleaved, soluble HIV-1 Env trimer, BG505 SOSIP.664 gp140, expresses multiple epitopes for broadly neutralizing but not non-neutralizing antibodies","volume":"9","author":"RW Sanders","year":"2013","journal-title":"PLOS Pathog"},{"key":"pcbi.1014632.ref048","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007054","article-title":"The T-cell response to HIV","volume":"2","author":"B Walker","year":"2012","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"3","key":"pcbi.1014632.ref049","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.immuni.2007.08.010","article-title":"Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy","volume":"27","author":"SG Deeks","year":"2007","journal-title":"Immunity"},{"issue":"6010","key":"pcbi.1014632.ref050","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1126\/science.1195271","article-title":"The major genetic determinants of HIV-1 control affect HLA class I peptide presentation","volume":"330","author":"International HIV Controllers Study","year":"2010","journal-title":"Science"},{"issue":"5","key":"pcbi.1014632.ref051","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/ng.795","article-title":"A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase","volume":"43","author":"T Hinkley","year":"2011","journal-title":"Nat Genet"},{"issue":"14","key":"pcbi.1014632.ref052","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.05.022","article-title":"Humoral and cellular immune memory to four COVID-19 vaccines","volume":"185","author":"Z Zhang","year":"2022","journal-title":"Cell"},{"key":"pcbi.1014632.ref053","doi-asserted-by":"crossref","first-page":"100793","DOI":"10.1016\/j.xcrm.2022.100793","article-title":"A comparative characterization of SARS-CoV-2-specific T cells induced by mRNA or inactive virus COVID-19 vaccines","volume":"3","author":"JME Lim","year":"2022","journal-title":"Cell Rep Med"},{"issue":"1","key":"pcbi.1014632.ref054","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4049\/jimmunol.180.1.309","article-title":"Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals","volume":"180","author":"S Kreiter","year":"2008","journal-title":"J Immunol"},{"issue":"11","key":"pcbi.1014632.ref055","doi-asserted-by":"crossref","first-page":"116545","DOI":"10.1016\/j.celrep.2025.116545","article-title":"Mechanism for evolution of diverse autologous antibodies upon broadly neutralizing antibody therapy of people with HIV","volume":"44","author":"D Kannan","year":"2025","journal-title":"Cell Rep"},{"key":"pcbi.1014632.ref056","article-title":"Enhanced HIV-1 control after antibody therapy is associated with autologous antibodies and reservoir clearance in the RIO trial","author":"MJ Fumagalli","year":"2026","journal-title":"medRxiv"},{"key":"pcbi.1014632.ref057","unstructured":"Fisher K, et al. Conference on Retroviruses and Opportunistic Infections; 2026."},{"key":"pcbi.1014632.ref058","article-title":"The reservoir of latent HIV","volume":"12","author":"J Chen","year":"2022","journal-title":"Front Cell Infect Microbiol"}],"updated-by":[{"DOI":"10.1371\/journal.pcbi.1014632","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000}}],"container-title":["PLOS Computational Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1014632","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T17:44:23Z","timestamp":1787247863000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pcbi.1014632"}},"subtitle":[],"editor":[{"given":"Juilee","family":"Thakar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,8,14]]},"references-count":58,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2026,8,14]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pcbi.1014632","relation":{},"ISSN":["1553-7358"],"issn-type":[{"value":"1553-7358","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,14]]}}}